UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
OR
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the Transition Period From to
Commission file number:
(Exact name of registrant as specified in its charter)
|
|
|
|
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer |
|
|
|
|
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including area code:
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
|
|
|
(NASDAQ Global Select Market) |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
☒ |
|
Accelerated filer |
|
☐ |
|
|
|
|
|
|||
|
Non-accelerated filer |
|
☐ |
|
Smaller reporting company |
|
|
|
|
|
|
|
|
|
|
|
Emerging growth company |
|
|
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
As of April 29, 2022, the registrant had
TABLE OF CONTENTS
|
|
|
|
Page |
|
|
Item 1. |
|
|
3 |
|
|
|
|
Consolidated Balance Sheets (unaudited) as of March 31, 2022 and December 31, 2021 |
|
3 |
|
|
|
|
5 |
|
|
|
|
|
6 |
|
|
|
|
|
7 |
|
|
|
|
Condensed Notes to the Consolidated Financial Statements (unaudited) |
|
9 |
|
Item 2. |
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
|
25 |
|
Item 3. |
|
|
48 |
|
|
Item 4. |
|
|
49 |
|
|
|
|
|
|
|
|
Item 1. |
|
|
50 |
|
|
Item 1A. |
|
|
51 |
|
|
Item 2. |
|
|
89 |
|
|
Item 3. |
|
|
90 |
|
|
Item 4. |
|
|
90 |
|
|
Item 5. |
|
|
90 |
|
|
Item 6. |
|
|
91 |
|
|
|
92 |
|||
2
INOGEN, INC.
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
Inogen, Inc.
Consolidated Balance Sheets
(unaudited)
(amounts in thousands)
|
|
March 31, |
|
|
December 31, |
|
||
|
|
2022 |
|
|
2021 |
|
||
|
Assets |
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
$ |
|
|
|
$ |
|
|
|
Marketable securities |
|
|
|
|
|
|
|
|
Accounts receivable, net |
|
|
|
|
|
|
|
|
Inventories, net |
|
|
|
|
|
|
|
|
Income tax receivable |
|
|
|
|
|
|
|
|
Prepaid expenses and other current assets |
|
|
|
|
|
|
|
|
Total current assets |
|
|
|
|
|
|
|
|
Property and equipment |
|
|
|
|
|
|
|
|
Rental equipment, net |
|
|
|
|
|
|
|
|
Manufacturing equipment and tooling |
|
|
|
|
|
|
|
|
Computer equipment and software |
|
|
|
|
|
|
|
|
Furniture and equipment |
|
|
|
|
|
|
|
|
Leasehold improvements |
|
|
|
|
|
|
|
|
Land and building |
|
|
|
|
|
|
|
|
Construction in process |
|
|
|
|
|
|
|
|
Total property and equipment |
|
|
|
|
|
|
|
|
Less accumulated depreciation |
|
( |
) |
|
|
( |
) |
|
Property and equipment, net |
|
|
|
|
|
|
|
|
Goodwill |
|
|
|
|
|
|
|
|
Intangible assets, net |
|
|
|
|
|
|
|
|
Operating lease right-of-use asset |
|
|
|
|
|
|
|
|
Other assets |
|
|
|
|
|
|
|
|
Total assets |
$ |
|
|
|
$ |
|
|
See accompanying condensed notes to the consolidated financial statements.
3
Inogen, Inc.
Consolidated Balance Sheets (continued)
(unaudited)
(amounts in thousands, except share and per share amounts)
|
|
March 31, |
|
|
December 31, |
|
||
|
|
2022 |
|
|
2021 |
|
||
|
Liabilities and stockholders' equity |
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses |
$ |
|
|
|
$ |
|
|
|
Accrued payroll |
|
|
|
|
|
|
|
|
Warranty reserve - current |
|
|
|
|
|
|
|
|
Operating lease liability - current |
|
|
|
|
|
|
|
|
Deferred revenue - current |
|
|
|
|
|
|
|
|
Income tax payable |
|
— |
|
|
|
|
|
|
Total current liabilities |
|
|
|
|
|
|
|
|
Long-term liabilities |
|
|
|
|
|
|
|
|
Warranty reserve - noncurrent |
|
|
|
|
|
|
|
|
Operating lease liability - noncurrent |
|
|
|
|
|
|
|
|
Earnout liability - noncurrent |
|
|
|
|
|
|
|
|
Deferred revenue - noncurrent |
|
|
|
|
|
|
|
|
Total liabilities |
|
|
|
|
|
|
|
|
Commitments and contingencies (Note 9) |
|
|
|
|
|
|
|
|
Stockholders' equity |
|
|
|
|
|
|
|
|
Common stock, $ shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively |
|
|
|
|
|
|
|
|
Additional paid-in capital |
|
|
|
|
|
|
|
|
Retained earnings |
|
|
|
|
|
|
|
|
Accumulated other comprehensive income |
|
|
|
|
|
|
|
|
Total stockholders' equity |
|
|
|
|
|
|
|
|
Total liabilities and stockholders' equity |
$ |
|
|
|
$ |
|
|
See accompanying condensed notes to the consolidated financial statements.
4
Inogen, Inc.
Consolidated Statements of Comprehensive Loss
(unaudited)
(amounts in thousands, except share and per share amounts)
|
|
Three months ended |
|
|||||
|
|
March 31, |
|
|||||
|
|
2022 |
|
|
2021 |
|
||
|
Revenue |
|
|
|
|
|
|
|
|
Sales revenue |
$ |
|
|
|
$ |
|
|
|
Rental revenue |
|
|
|
|
|
|
|
|
Total revenue |
|
|
|
|
|
|
|
|
Cost of revenue |
|
|
|
|
|
|
|
|
Cost of sales revenue |
|
|
|
|
|
|
|
|
Cost of rental revenue, including depreciation of $ |
|
|
|
|
|
|
|
|
Total cost of revenue |
|
|
|
|
|
|
|
|
Gross profit |
|
|
|
|
|
|
|
|
Gross profit-sales revenue |
|
|
|
|
|
|
|
|
Gross profit-rental revenue |
|
|
|
|
|
|
|
|
Total gross profit |
|
|
|
|
|
|
|
|
Operating expense |
|
|
|
|
|
|
|
|
Research and development |
|
|
|
|
|
|
|
|
Sales and marketing |
|
|
|
|
|
|
|
|
General and administrative |
|
|
|
|
|
|
|
|
Total operating expense |
|
|
|
|
|
|
|
|
Loss from operations |
|
( |
) |
|
|
( |
) |
|
Other income (expense) |
|
|
|
|
|
|
|
|
Interest income |
|
|
|
|
|
|
|
|
Other income (expense) |
|
( |
) |
|
|
( |
) |
|
Total other expense, net |
|
( |
) |
|
|
( |
) |
|
Loss before provision (benefit) for income taxes |
|
( |
) |
|
|
( |
) |
|
Provision (benefit) for income taxes |
|
|
|
|
|
( |
) |
|
Net loss |
|
( |
) |
|
|
( |
) |
|
Other comprehensive income (loss), net of tax |
|
|
|
|
|
|
|
|
Change in foreign currency translation adjustment |
|
( |
) |
|
|
( |
) |
|
Change in net unrealized gains (losses) on foreign currency hedging |
|
( |
) |
|
|
|
|
|
Less: reclassification adjustment for net (gains) losses included in net income |
|
|
|
|
|
( |
) |
|
Total net change in unrealized gains (losses) on foreign currency hedging |
|
( |
) |
|
|
|
|
|
Change in net unrealized gains (losses) on marketable securities |
|
( |
) |
|
|
|
|
|
Total other comprehensive income (loss), net of tax |
|
( |
) |
|
|
|
|
|
Comprehensive loss |
$ |
( |
) |
|
$ |
( |
) |
|
|
|
|
|
|
|
|
|
|
Basic net loss per share attributable to common stockholders (Note 6) |
$ |
( |
) |
|
$ |
( |
) |
|
Diluted net loss per share attributable to common stockholders (Note 6) |
$ |
( |
) |
|
$ |
( |
) |
|
Weighted average number of shares used in calculating net loss per share attributable to common stockholders: |
|
|
|
|
|
|
|
|
Basic common shares |
|
|
|
|
|
|
|
|
Diluted common shares |
|
|
|
|
|
|
|
See accompanying condensed notes to the consolidated financial statements.
5
Inogen, Inc.
Consolidated Statements of Stockholders’ Equity
(unaudited)
(amounts in thousands, except share amounts)
|
|
Three months ended March 31, 2022 and March 31, 2021 |
|
|||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
|
|
other |
|
|
Total |
|
||||||||
|
|
Common stock |
|
|
paid-in |
|
|
Retained |
|
|
comprehensive |
|
|
stockholders' |
|
|||||||||
|
|
Shares |
|
|
Amount |
|
|
capital |
|
|
earnings |
|
|
income |
|
|
equity |
|
||||||
|
Balance, December 31, 2020 |
|
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
Stock-based compensation |
|
— |
|
|
|
— |
|
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
Employee stock purchases |
|
|
|
|
|
— |
|
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
Restricted stock awards issued, net of forfeitures |
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
Vesting of restricted stock units |
|
|
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
Shares withheld related to net restricted stock settlement |
|
( |
) |
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
Stock options exercised |
|
|
|
|
|
— |
|
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
Net loss |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
|
Other comprehensive income |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
Balance, March 31, 2021 |
|
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2021 |
|
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
Stock-based compensation |
|
— |
|
|
|
— |
|
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
Employee stock purchases |
|
|
|
|
|
— |
|
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
Vesting of restricted stock units |
|
|
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
Shares withheld related to net restricted stock settlement |
|
( |
) |
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
Stock options exercised |
|
|
|
|
|
— |
|
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
Net loss |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
|
Other comprehensive loss |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
|
Balance, March 31, 2022 |
|
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying condensed notes to the consolidated financial statements.
6
Inogen, Inc.
Consolidated Statements of Cash Flows
(unaudited)
(amounts in thousands)
|
|
Three months ended March 31, |
|
|||||
|
|
2022 |
|
|
2021 |
|
||
|
Cash flows from operating activities |
|
|
|
|
|
|
|
|
Net loss |
$ |
( |
) |
|
$ |
( |
) |
|
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
|
|
|
|
Loss on rental units and other fixed assets |
|
|
|
|
|
|
|
|
Gain on sale of former rental assets |
|
( |
) |
|
|
( |
) |
|
Provision for sales revenue returns and doubtful accounts |
|
|
|
|
|
|
|
|
Provision for rental revenue adjustments |
|
— |
|
|
|
|
|
|
Provision for inventory losses |
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
|
|
|
|
|
|
|
Deferred income taxes |
|
— |
|
|
|
( |
) |
|
Change in fair value of earnout liability |
|
|
|
|
|
|
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
( |
) |
|
|
( |
) |
|
Inventories |
|
( |
) |
|
|
( |
) |
|
Income tax receivable |
|
( |
) |
|
|
|
|
|
Prepaid expenses and other current assets |
|
|
|
|
|
|
|
|
Operating lease right-of-use asset |
|
|
|
|
|
( |
) |
|
Other noncurrent assets |
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses |
|
|
|
|
|
( |
) |
|
Accrued payroll |
|
( |
) |
|
|
|
|
|
Warranty reserve |
|
( |
) |
|
|
|
|
|
Deferred revenue |
|
( |
) |
|
|
|
|
|
Income tax payable |
|
( |
) |
|
|
|
|
|
Operating lease liability |
|
( |
) |
|
|
|
|
|
Net cash provided by (used in) operating activities |
|
( |
) |
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
|
|
|
Maturities of marketable securities |
|
— |
|
|
|
|
|
|
Investment in intangible assets |
|
— |
|
|
|
( |
) |
|
Investment in property and equipment |
|
( |
) |
|
|
( |
) |
|
Production and purchase of rental equipment |
|
( |
) |
|
|
( |
) |
|
Proceeds from sale of former assets |
|
|
|
|
|
|
|
|
Net cash provided by (used in) investing activities |
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(continued on next page) |
|
||||||
See accompanying condensed notes to the consolidated financial statements.
7
Inogen, Inc.
Consolidated Statements of Cash Flows (continued)
(unaudited)
(amounts in thousands)
|
|
Three months ended March 31, |
|
|||||
|
|
2022 |
|
|
2021 |
|
||
|
Cash flows from financing activities |
|
|
|
|
|
|
|
|
Proceeds from stock options exercised |
|
|
|
|
|
|
|
|
Proceeds from employee stock purchases |
|
|
|
|
|
|
|
|
Payment of employment taxes related to release of restricted stock |
|
( |
) |
|
|
( |
) |
|
Net cash provided by (used in) financing activities |
|
( |
) |
|
|
|
|
|
Effect of exchange rates on cash |
|
|
|
|
|
( |
) |
|
Net increase (decrease) in cash and cash equivalents |
|
( |
) |
|
|
|
|
|
Cash and cash equivalents, beginning of period |
|
|
|
|
|
|
|
|
Cash and cash equivalents, end of period |
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosures of cash flow information |
|
|
|
|
|
|
|
|
Cash paid during the period for income taxes, net of refunds received |
$ |
|
|
|
$ |
|
|
|
Supplemental disclosure of non-cash transactions |
|
|
|
|
|
|
|
|
Property and equipment in accounts payable and accrued liabilities |
|
|
|
|
|
|
|
See accompanying condensed notes to the consolidated financial statements.
8
Inogen, Inc.
Condensed Notes to the Consolidated Financial Statements
(unaudited)
(amounts in thousands, except share and per share amounts)
1. Business overview
Inogen, Inc. (Company or Inogen) was incorporated in Delaware on November 27, 2001. The Company is a medical technology company that primarily develops, manufactures and markets innovative portable oxygen concentrators (POCs) used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Traditionally, these patients have relied on stationary oxygen concentrator systems for use in the home and oxygen tanks or cylinders for mobile use, which the Company calls the delivery model. The tanks and cylinders must be delivered regularly and have a finite amount of oxygen, which requires patients to plan activities outside of their homes around delivery schedules and a finite oxygen supply. Additionally, patients must attach long, cumbersome tubing to their stationary concentrators simply to enable mobility within their homes. The Company’s proprietary Inogen One® systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a single battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. The Company’s Inogen One systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen, thereby improving patient quality of life and fostering mobility.
The Company incorporated Inogen Europe Holding B.V., a Dutch limited liability company, on
2. Basis of presentation and summary of significant accounting policies
The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP).
The results of operations for the three months ended March 31, 2022 shown in this report are not necessarily indicative of results to be expected for the full year ending December 31, 2022. In the opinion of the Company’s management, the information contained herein reflects all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of the Company’s results of operations, financial position, cash flows and stockholders’ equity. Certain footnote disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to Securities and Exchange Commission (SEC) rules and regulations relating to interim financial statements. The accompanying consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 24, 2022. Except as further described below, there have been no significant changes in the Company’s accounting policies from those disclosed in its Annual Report on Form 10-K filed with the SEC on February 24, 2022.
Basis of consolidation
The consolidated financial statements include the accounts of Inogen, Inc. and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated.
Use of estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, warranty reserves and expense, determining the stand-alone selling price (SSP) and service period of performance obligations, rental asset valuations and write-downs, accounts receivable allowances for bad debts, returns and adjustments, impairment of long-lived assets, stock-based compensation expense, income taxes, fair value of acquired intangible assets and goodwill and fair value of earnout liabilities. Actual results could differ from these estimates.
9
Inogen, Inc.
Condensed Notes to the Consolidated Financial Statements (continued)
(unaudited)
(amounts in thousands, except share and per share amounts)
Business segments
The Company operates and reports in only
3. Fair value measurements
Accounting Standards Codification (ASC) 820 — Fair Value Measurements and Disclosures creates a single definition of fair value, establishes a framework for measuring fair value in U.S. GAAP and expands disclosures about fair value measurements. ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement, and states that a fair value measurement is to estimate the price at which an orderly transaction to sell an asset or to transfer the liability would take place between market participants at the measurement date under current market conditions. Assets and liabilities adjusted to fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by ASC 820, are as follows:
|
Level input |
|
Input definition |
|
Level 1 |
|
Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date. |
|
|
|
|
|
Level 2 |
|
Inputs, other than quoted prices included in Level 1, that are observable for the asset or liability through corroboration with market data at the measurement date. |
|
|
|
|
|
Level 3 |
|
Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. |
The Company’s financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses. The carrying values of its financial instruments approximate fair value based on their short-term nature.
Cash, cash equivalents and marketable securities
The Company obtained the fair value of its available-for-sale investments, which are not in active markets, from a third-party professional pricing service using quoted market prices for identical or comparable instruments, rather than direct observations of quoted prices in active markets. The Company's professional pricing service gathers observable inputs for all of its fixed income securities from a variety of industry data providers (e.g., large custodial institutions) and other third-party sources. Once the observable inputs are gathered, all data points are considered, and the fair value is determined. The Company validates the quoted market prices provided by its primary pricing service by comparing their assessment of the fair values against the fair values provided by its investment managers. The Company's investment managers use similar techniques to its professional pricing service to derive pricing as described above. As all significant inputs were observable, derived from observable information in the marketplace or supported by observable levels at which transactions are executed in the marketplace, the Company has classified its marketable securities within Level 2 of the fair value hierarchy.
10
Inogen, Inc.
Condensed Notes to the Consolidated Financial Statements (continued)
(unaudited)
(amounts in thousands, except share and per share amounts)
The following table summarizes fair value measurements by level for the assets measured at fair value on a recurring basis for cash, cash equivalents and marketable securities:
|
|
|
As of March 31, 2022 |
|
|||||||||||||||||
|
|
|
|
|
|
|
Gross |
|
|
|
|
|
|
Cash |
|
|
|
|
|
||
|
|
|
Adjusted |
|
|
unrealized |
|
|
|
|
|
|
and cash |
|
|
Marketable |
|
||||
|
|
|
cost |
|
|
losses |
|
|
Fair value |
|
|
equivalents |
|
|
securities |
|
|||||
|
Cash |
|
$ |
|
|
|
$ |
— |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
— |
|
|
Level 1: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market accounts |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 2: |
|
|
|
|
|
|
|
|||||||||||||